Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Shares in biotech company Recursion Pharmaceuticals ( RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

This letter proposes a novel random Fourier features (RFF) based sparsity-aware Kernel recursive adaptive filtering algorithm which employs generalized maximum Versoria criterion (GMVC) as an ...

This paper proposes a recursive algorithm for estimating the adaptive function coefficients autoregressive (AFAR) models. Due to its recursive nature, its arithmetic complexity is relatively lower ...